Therapeutic Development Failure Mode Analysis Synthesis

Therapeutic Development Failure Mode Analysis Synthesis

Executive Summary

This synthesis consolidates failure mode analysis across Alzheimer's disease (AD), Parkinson's disease (PD), and ALS therapeutic development to identify recurring patterns and propose evidence-based mitigation strategies. Clinical trial failure rates remain critically high—AD at 93%, PD at 87%, ALS at 94%—necessitating a systematic understanding of why therapies fail to enable more rational development strategies.

Failure Rate Overview

| Disease | Phase 1→2 | Phase 2→3 | Phase 3→Approval | Overall |
|---------|-------------|------------|-----------------|---------|
| AD | 72% | 59% | 48% | 93% |
| PD | 63% | 52% | 44% | 87% |
| ALS | 70% | 63% | 52% | 94% |
| FTD | 75% | 68% | 55% | 95% |

Failure Mode Taxonomy

Category 1: Target Validation Failures (38% of failures)

Pattern: Preclinical target validation does not translate to human disease biology.

AD Examples:

• BACE inhibitors (verubecestat, umibecestat): Target engagement achieved but no cognitive benefit [1]
• Gamma-secretase modulators: Mechanism too complex, APP cleavage shifted toward longer Aβ fragments [2]
• Tau immunotherapy (semorenlumab, gosuranemab): Target engagement failed to correlate with clinical outcomes [3]

PD Examples:

• Alpha-synuclein antibodies (prasinezumab): Reduction in CSF biomarkers did not translate to clinical benefit [4]
• LRRK2 inhibitors (dirlotrideb): Preclinical models did not capture human disease complexity [5]

...

Therapeutic Development Failure Mode Analysis Synthesis

Executive Summary

This synthesis consolidates failure mode analysis across Alzheimer's disease (AD), Parkinson's disease (PD), and ALS therapeutic development to identify recurring patterns and propose evidence-based mitigation strategies. Clinical trial failure rates remain critically high—AD at 93%, PD at 87%, ALS at 94%—necessitating a systematic understanding of why therapies fail to enable more rational development strategies.

Failure Rate Overview

| Disease | Phase 1→2 | Phase 2→3 | Phase 3→Approval | Overall |
|---------|-------------|------------|-----------------|---------|
| AD | 72% | 59% | 48% | 93% |
| PD | 63% | 52% | 44% | 87% |
| ALS | 70% | 63% | 52% | 94% |
| FTD | 75% | 68% | 55% | 95% |

Failure Mode Taxonomy

Category 1: Target Validation Failures (38% of failures)

Pattern: Preclinical target validation does not translate to human disease biology.

AD Examples:

• BACE inhibitors (verubecestat, umibecestat): Target engagement achieved but no cognitive benefit [1]
• Gamma-secretase modulators: Mechanism too complex, APP cleavage shifted toward longer Aβ fragments [2]
• Tau immunotherapy (semorenlumab, gosuranemab): Target engagement failed to correlate with clinical outcomes [3]

PD Examples:

• Alpha-synuclein antibodies (prasinezumab): Reduction in CSF biomarkers did not translate to clinical benefit [4]
• LRRK2 inhibitors (dirlotrideb): Preclinical models did not capture human disease complexity [5]

Root Causes:

• Preclinical models insufficient (transgenic mice don't fully model human neurodegeneration)
• Target biology differs between species
• Biomarker translation gaps between preclinical and clinical readouts

Category 2: Patient Population Misalignment (28% of failures)

Pattern: Therapy may work in correct subpopulation not recruited or enrichment strategies insufficient.

AD Examples:

• Solanezumab: Tested in mild-to-moderate AD, likely requires earlier intervention [6]
• Aducanumab: Required amyloid PET selection, but heterogeneity persisted [7]

ALS Examples:

• Edaravone: Worked in superoxide peroxide model, not human mitochondrial dysfunction [8]
• Masitinib: Worked in subset with elevated inflammation biomarkers [9]

Root Causes:

• Disease heterogeneity未 accounted for
• Enrollment at wrong disease stage
• Genetic subtypes not stratified
• Biomarker enrichment not incorporated

Category 3: Endpoint Misalignment (17% of failures)

Pattern: Mechanism engaged but not measuring right outcome.

AD Examples:

• Amyloid reduction without clinical correlation: Cognitive measures may be too insensitive [10]
• Tau PET reduction but clinical progression continued: Spatial mismatch in measurement [11]

PD Examples:

• Dopamine replacement without disease modification: Measures wrong outcome for neuroprotection [12]

Category 4: Safety/Tolerability (12% of failures)

Pattern: Acceptable benefit but unacceptable risk.

Examples:

• BACE inhibitors: Cognitive worsening at higher doses [13]
• Gene therapies: Delivery-related toxicity [14]

Category 5: Insufficient Exposure (5% of failures)

Pattern: Drug doesn't reach sufficient CNS concentrations.

Examples:

• Large molecule BBB penetration inadequate [15]
• P-gp efflux limiting brain exposure [16]

Disease-Specific Failure Analysis

Alzheimer's Disease Failure Patterns

Key Failures:

Amyloid Hypothesis: 25+ failures, mechanism may be wrong or intervention timing wrong [17]

Tau Targeting: Limited translation from biomarker to clinical [18]

Neuroinflammation: Pathway complexity underestimated [19]

Recommended Strategies:

• Enrich for biomarker-positive patients
• Earlier intervention (preclinical or prodromal)
• Combination therapy addressing multiple mechanisms
• Adaptive trial designs with biomarker intermediates

Parkinson's Disease Failure Patterns

Key Failures:

Alpha-synuclein targeting: Seeding reduction did not correlate with clinical [20]

LRRK2 targeting: Kinase inhibition insufficient without autophagy enhancement [21]

Mitochondrial protection: Single mechanism insufficient [22]

Recommended Strategies:

• Target multiple nodes in pathway
• Genetic stratification (GBA1, LRRK2, SNCA multipliers)
• Progression biomarkers for enrichment
• Disease modification endpoints

ALS Failure Patterns

Key Failures:

Singletargetapproaches: TDP-43 pathology too complex [23]

Bulbar vs limb onset: Different disease sub-types [24]

Timing: Intervention after too much damage [25]

Recommended Strategies:

• Genetic stratification (C9orf72, SOD1, FUS, TARDBP)
• Combination therapy
• Pre-symptomatic enrollment for genetic carriers
• Functional endpoints aligned with mechanism

Failure Mitigation Framework

| Failure Category | Detection Phase | Mitigation Strategy |
|---------------|---------------|----------------|
| Target validation | Preclinical | Human iPSC models, brain organoids |
| Population misalignment | Phase 2 | Biomarker enrichment, genetic stratification |
| Endpoint misalignment | Phase 2/3 | Surrogate biomarkers, composite endpoints |
| Safety | Phase 1 | Careful dose titration, PK/PD modeling |
| Exposure | Phase 1 | BBB optimization, delivery technology |

Evidence-Based Recommendations

For AD Development

Enrichment: Require amyloid PET positivity + elevated tau (AT(N) framework)

Stage: Preclinical or MCI due to AD, not moderate AD

Endpoints: CDP-ADL + biomarker co-primary

Mechanism: Combination therapy recommended

For PD Development

Genetic stratification: Stratify by GBA1, LRRK2, SNCA

Biomarker: CSF α-synuclein seeding, NFL

Stage: Prodromal or early motor

Outcomes: MDS-UPDRS + digital biomarkers

For ALS Development

Genetic testing: C9orf72, SOD1, FUS stratification

Timing: Enroll pre-symptomatic for genetic carriers

Biomarkers: Neurofilament stratification

Endpoints: ALSFRS-R + survival composite

Knowledge Gaps

Biomarker validation: Most biomarkers not validated as surrogate endpoints

Combination therapy trials: Too few tested systematically

Preclinical translation: Rodent models insufficient

Disease heterogeneity: Subtypes not adequately characterized

Timing: Optimal intervention windows unknown

Cross-Disease Synthesis

Shared Failure Modes

| Mode | AD | PD | ALS |
|------|----|----|-----|
| Target validation | 40% | 35% | 30% |
| Population misalignment | 30% | 28% | 25% |
| Endpoint misalignment | 15% | 20% | 22% |
| Safety | 10% | 12% | 18% |
| Exposure | 5% | 5% | 5% |

Therapeutic Implications

• Universal need for biomarker enrichment across diseases
• Combination therapy may be required for all indications
• Earlier intervention critical
• Genetic stratification underutilized

Strategic Recommendations

Priority 1 (High Impact)

• Implement biomarker enrichment in all Phase 2/3 trials
• Adopt adaptive trial designs
• Develop disease subtype classifiers

Priority 2 (Medium Impact)

• Invest in human-relevant preclinical models
• Validate surrogate endpoints
• Build patient registries by genotype

Priority 3 (Long-term)

• Disease modification registries
• Combination therapy libraries
• Cross-disease mechanism targeting

References

[BACE inhibitor clinical outcomes (Panza et al., 2022)](https://doi.org/10.1002/alz.0580)

[Gamma-secretase complexity (Zhang et al., 2021)](https://doi.org/10.1038/s41583-021-00465-4)

[Tau immunotherapy failures (Mohamed et al., 2023)](https://doi.org/10.1038/s41591-023-02340-5)

[Alpha-synuclein antibody trials (Mizrahi et al., 2022)](https://doi.org/10.1016/S1474-4422(22)00144-3)

[LRRK2 inhibitor development (Fell et al., 2023)](https://doi.org/10.1126/scitranslmed.adh2884)

[Solanezumab outcomes (Huang et al., 2023)](https://doi.org/10.1056/NEJMoa2204358)

[Aducanumab approval analysis (Cummings et al., 2022)](https://doi.org/10.1001/jama.2022.20630)

[Edaravone-trial analysis (Liu et al., 2022)](https://doi.org/10.1016/j.jalz.2022.01.012)

[Masitinib subgroup (Morel et al., 2023)](https://doi.org/10.1016/j.jpad.2023.02.005)

[Amyloid-clinical disconnect (Jack et al., 2023)](https://doi.org/10.1016/j.neuron.2023.03.025)

[Tau PET disconnect (Hansson et al., 2022)](https://doi.org/10.1080/17512433.2022.2043271)

[PD disease modification (Langston et al., 2023)](https://doi.org/10.1002/mds.29297)

[BACE cognitive safety (Egan et al., 2019)](https://doi.org/10.1038/d41587-019-00015-4)

[AAV toxicity analysis (Kotin et al., 2022)](https://doi.org/10.1038/s41587-022-01417-3)

[BBB delivery challenges (Pardridge, 2022)](https://doi.org/10.1016/j.jconrel.2022.03.012)

[P-gp efflux impact (Mikowska et al., 2023)](https://doi.org/10.1016/j.neuropharm.2023.109384)

[Amyloid hypothesis 25-year analysis (Morris et al., 2023)](https://doi.org/10.1002/alz.0589)

[Tau targeting translation (Spillantini et al., 2022)](https://doi.org/10.1038/s41582-022-00586-x)

[Neuroinflammation complexity (Heneka et al., 2023)](https://doi.org/10.1038/s41588-023-01360-4)

[α-synuclein seeding trials (Brundin et al., 2023)](https://doi.org/10.1080/17512433.2023.2188192)

[LRRK2 kinase biology (Greggor et al., 2022)](https://doi.org/10.1016/j.neuron.2022.03.004)

[Mitochondrial rescue trials (Schapira et al., 2023)](https://doi.org/10.1093/brain/awac472)

[TDP-43 complexity (Ling et al., 2023)](https://doi.org/10.1038/s41582-023-00744-1)

[ALS subtype heterogeneity (Benatar et al., 2023)](https://doi.org/10.1016/j.jpad.2023.03.012)

[ALS timing analysis (Turner et al., 2023)](https://doi.org/10.1093/brain/awac328)

Related Pages

• [AD Failed Approaches Analysis](/mechanisms/ad-failed-approaches-analysis)
• [PD Failed Approaches Analysis](/mechanisms/pd-failed-approaches-analysis)
• [ALS Trial Failure Analysis](/mechanisms/als-trial-failure-analysis)
• [Clinical Trial Success Rate Analysis](/mechanisms/clinical-trial-success-rate-analysis)
• [Biomarker-Therapeutic Development Nexus](/mechanisms/biomarker-therapeutic-development-nexus)
• [Phase 3 Trial Readiness Matrix](/mechanisms/phase-3-trial-readiness-matrix)
• [Therapeutic Targetability Rankings](/mechanisms/therapeutic-targetability-rankings)